NATERA INC (Common Stock) – ticker 45E (NTRA)
Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Natera (NTRA) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Natera Looks Compelling As Oncology Testing Momentum Keeps Building
NTRA's oncology franchise, led by Signatera MRD testing, is the main bull case at this point. As long as they keep building on their testing volumes, I believe this should support a long runway in cancer monitoring and recurrence detection. NTRA's 2025 also included new product launches and added Medicare coverage, advanced early cancer detection, and broadened its molecular diagnostics portfolio.
Natera, Inc. $NTRA Position Reduced by Bank of Hawaii
Bank of Hawaii reduced its stake in shares of Natera, Inc. (NASDAQ: NTRA) by 18.6% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,835 shares of the medical research company's stock after selling 4,072 shares during
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at Leerink Global Healthcare Conference 2026 Transcript
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Natera, Inc. (NTRA) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera (NTRA) Tops Q4 Earnings and Revenue Estimates
Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago.
Natera (NTRA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unveiling Natera (NTRA) Q4 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Natera (NTRA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Billionaire Stanley Druckenmiller Is Betting Big on These 2 Stocks
One investment is a fast-growing genetic testing company that's now generating cash flow and has a scalable business model. The leading semiconductor foundry's sales are booming on AI-led demand, but expanding cash-flow margins will be a challenge.
Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test
NTRA submits FDA PMA for Signatera CDx, aiming to guide bladder cancer treatment with MRD testing after positive phase 3 trial results.
